Personalized cell therapy shows promise for Hard-to-Treat cancers

NCT ID NCT06334783

Terminated Disease control Sponsor: Hervor Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a personalized cancer treatment called tumor-infiltrating lymphocyte (TIL) therapy. Doctors took immune cells from each patient's own tumor, grew them in a lab, and infused them back to fight the cancer. The study enrolled only 5 adults with advanced solid tumors and was terminated early, so the full safety and effectiveness are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor-infiltrating lymphocyte cells (a type of immune cell taken from the patient's own tumor, grown in a lab, and given back to fight cancer)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small trial (only 5 people) that was terminated, so results are limited. The therapy may not work for all tumor types and can cause serious side effects from the immune system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, Guangdong, China
Nanjing Jinling Hospital

Nanjing, Jiangsu, 210000, China
Wowen's hospital, School of medicine, Zhejiang University

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.